InMed Pharmaceuticals (NASDAQ:INM) Stock Price Up 2.6% – Here’s Why

02 Jul 2026, 05:01 by Mitch Edgeman · The Markets Daily

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) traded up 2.6% on Wednesday . The company traded as high as $1.59 and last traded at $1.59. 57,764 shares traded hands during mid-day trading, an increase of 6% from the average daily volume of 54,301 shares. The stock had previously closed at $1.55.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded InMed Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Check Out Our Latest Stock Report on InMed Pharmaceuticals

InMed Pharmaceuticals Stock Up 2.6%

The stock has a market capitalization of $5.26 million, a price-to-earnings ratio of -0.55 and a beta of 0.95. The company has a 50 day moving average of $1.26 and a 200 day moving average of $1.06.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($94.44) by $93.75. InMed Pharmaceuticals had a negative return on equity of 80.85% and a negative net margin of 132.87%.

Insider Buying and Selling at InMed Pharmaceuticals

In other InMed Pharmaceuticals news, major shareholder Adar1 Capital Management, Llc purchased 468,551 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were purchased at an average price of $1.54 per share, for a total transaction of $721,568.54. Following the completion of the acquisition, the insider owned 800,000 shares of the company’s stock, valued at approximately $1,232,000. This represents a 141.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Vivo Opportunity, Llc acquired 32,500 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were acquired at an average price of $1.52 per share, with a total value of $49,400.00. Following the completion of the purchase, the insider owned 718,444 shares of the company’s stock, valued at $1,092,034.88. This trade represents a 4.74% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 717,778 shares of company stock valued at $1,113,123 over the last three months. Corporate insiders own 0.85% of the company’s stock.

Institutional Trading of InMed Pharmaceuticals

An institutional investor recently bought a new stake in InMed Pharmaceuticals stock. Sabby Management LLC purchased a new position in InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 219,998 shares of the company’s stock, valued at approximately $482,000. InMed Pharmaceuticals makes up about 0.6% of Sabby Management LLC’s portfolio, making the stock its 12th biggest holding. Sabby Management LLC owned approximately 7.86% of InMed Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 20.12% of the company’s stock.

InMed Pharmaceuticals Company Profile

(Get Free Report)

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, that is dedicated to the discovery and development of novel therapeutics derived from cannabinoids. Leveraging a proprietary drug discovery engine, the company works to identify, design and optimize cannabinoid-based molecules with the goal of addressing diseases that have significant unmet medical needs. InMed’s integrated business model combines research, development and manufacturing capabilities under one roof to streamline the progression of promising assets from preclinical studies into human trials.